Novozymes A/S
NZYM-B.CO
NASDAQ Copenhagen397.40
DKK
-1.20
- -
Novozymes A/S
NZYM-B.CO
(NASDAQ Copenhagen)
Recent
price
397.40
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Novozymes A/S, a biotechnology company specializing in the research, development and production of industrial enzymes, microorganisms and biopharmaceutical ingredients, serves industries including household care, bioenergy, food and beverages, agriculture, animal health, pharmaceuticals and human nutrition with products such as over 700 enzyme variants, biopolymers and proteins; biosolutions for dairy, baking, beverages, meat processing, plant-based foods and functional ingredients; and nutraceuticals encompassing natural botanicals, vitamins and probiotics. Founded in 2000 as a spin-off from Novo Nordisk and formerly headquartered in Bagsværd, Denmark, the company operates globally across more than 130 markets with facilities in regions including Europe, North America, China, India and Brazil. In a transformative development, Novozymes merged with Chr. Hansen in January 2024 to form Novonesis A/S, creating a leading global biosolutions partner with enhanced capabilities in food, health, household care, agriculture and energy sectors, diversified portfolio and projected synergies of up to EUR 200 million in revenue and EUR 80-90 million in cost savings within three to four years. The combined entity, trading under the NZYM-B.CO ticker, continues to advance biotech innovations, launching 18 new solutions in 2023 and reporting strong Q1 2025 organic sales growth of 11% while pursuing a 5-8% annual growth strategy through 2025.